Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company’s ambitious plans for 2026.
January 12, 2026 08:36 ET | Source: Moleculin Biotech, Inc.

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE...
January 12, 2026 07:30 ET | Source: EDAP TMS S.A.

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance 36% to 38% Annual YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal...
January 08, 2026 08:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been...
January 08, 2026 07:00 ET | Source: AccuStem Sciences, Inc.

AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)

PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today...
January 07, 2026 16:00 ET | Source: Immuneering Corporation

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
January 07, 2026 12:03 ET | Source: AB Science

AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UN QUATRIÈME CAS CONSÉCUTIF DE RÉPONSE AVEC LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN...
January 07, 2026 12:03 ET | Source: AB Science

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA...
January 07, 2026 09:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences
January 07, 2026 08:05 ET | Source: ARTIS Ventures

Luminate Raises $21 Million in Funding to Expand Home Cancer Treatment

GALWAY, IRELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Luminate, a healthcare technology company which helps patients to receive cancer treatments at home, has raised $21 million in an expanded Series A...